Abstract Submission Opens July 27, 2018
Abstract Submission Deadline Midnight (PST), December 3, 2018
Abstract submission Extended Deadline Midnight (PST), December 17, 2018
Abstract Notifications February, 2019
General Information for Main INS Congress Abstract Submissions
In addition to traditional poster presentations, the INS Scientific Program and Biennial Congress Committees have reserved room on the program for free oral presentations. Each oral presenter will be allowed 8 minutes of lecture time, 8 slides, and a 2-minute question and answer period. Please check the appropriate box on the submission form to indicate whether your proposal should be considered for oral and poster presentation or only for poster presentation. The committee will accept a total of approximately 100-120 oral presentations.
Paper abstracts previously presented or published may not be submitted without modification. Original work must be changed or expanded, resulting in a new abstract.
Content without Commercial Bias*
The content of abstracts, posters and oral presentations must promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. Presentations must avoid commercialism and may not contain any logos, commercial branding or messaging.
Abstracts, posters and oral presentations must give a balanced view of therapeutic options. If the content includes trade names, where available, trade names from several companies should be used, not just trade names from a single company, and they should be limited to the material and methods section only. Generic terms contribute to impartiality, and should be used in title and in the body of the abstract.
Policy on Commercial Support*
Presentations that constitute promotion and advertising will not be accepted. If the cost of a presentation has been underwritten to any extent, a clear acknowledgement stating the support and identifying the source should be included in the abstract (e.g., "The support of [corporation or institution] for this project is gratefully acknowledged."). Statements made in presentations are the sole responsibility of the author or presenter. Statements should not be viewed as or considered representative of any formal stance or position taken on any subject, issue, or product by the International Neuromodulation Society.
*From ACCME Standards for Commercial Support SM
Submissions will be reviewed and rated by members of the Scientific, Biennial Congress, and Education and CME Committees and Neuromodulation Editorial Board who have expertise in the clinical area to which the submission belongs. Each submission will be reviewed for its scientific or clinical importance, ethical practice, study design and conflict of interest. Any conflicts of interest must be resolved prior to an abstract's acceptance.
The INS Scientific Program Committee recognizes that submissions of high quality, accepted for presentation at this meeting, should be acknowledged. All accepted abstracts will be published on the Society's website and in the online version of the INS journal, Neuromodulation: Technology at the Neural Interface. INS will retain the copyright of published abstracts.
Notification of Peer Review Outcome
Notification of abstract acceptance or non-acceptance will be emailed to the person listed on the abstract as Presenting author in mid-February 2019.
Industry employees' participation as presenters in the scientific program is only allowed if they agree to speak only on completely non-commercial topics, unrelated to any of their company's products, such as:
- basic science research (e.g. pre-clinical research, or therapy discovery)
- process or methodologies of research unrelated to a specific disease or device
- mechanisms of action unrelated to a specific product
Abstract-related questions can be directed to the Congress Secretariat.